And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is particularly modest. We hope to catch up on our fast-growing reading list, take a few naps, and hang with a short person or two. We may also putter around the castle. And what about you? Spring is edging closer, so perhaps this is a good time to plan a getaway or get a head start on cleaning out the closets. You could also enjoy a moving picture or make time for someone special. Life is short, you know. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you soon …
Sanofi (SNY) suffered a major setback in its bid to market its controversial dengue vaccine in the U.S., as a Food and Drug Administration advisory committee recommended against approval for adults, STAT writes. The drug maker had asked the agency to approve Dengvaxia for people aged 9 to 45. But the advisory panel recommended the agency license the vaccine only for people ages 9 to less than 17. Dengvaxia is the first dengue vaccine to make it to market anywhere in the world, but has accompanied by enormous problems and scandal.
About the Author Reprints
